Skip to content

Drug interactions

Lapatinib + Lenacapavir

Severity: Moderate

Lapatinib and Lenacapavir: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Lenacapavir is a moderate CYP3A inhibitor and may raise lapatinib exposure, with effects persisting for months after subcutaneous dosing. This may increase lapatinib adverse effects including QT prolongation.

What this interaction means in plain words

Lapatinib and Lenacapavir can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Lapatinib belongs to Oncology; Lenacapavir belongs to Anti Virals.

Evidence level: Low

Why it happens

Lenacapavir inhibits CYP3A4, reducing lapatinib metabolism.

What to do

Monitor for lapatinib toxicity, including ECG and liver tests, and consider a lapatinib dose reduction if adverse effects occur.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Lapatinib and Lenacapavir, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Lapatinib with Lenacapavir?

MediHelp rates the interaction as moderate. Lapatinib and Lenacapavir can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lenacapavir is a moderate CYP3A inhibitor and may raise lapatinib exposure, with effects persisting for months after subcutaneous dosing. This may increase lapatinib adverse effects including QT prolongation.

How serious is the interaction between Lapatinib and Lenacapavir?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for lapatinib toxicity, including ECG and liver tests, and consider a lapatinib dose reduction if adverse effects occur.

What other medicines interact with Lapatinib?

MediHelp also lists interactions of Lapatinib with, for example, Dofetilide, Ibutilide, Pimozide. The full list is on the Lapatinib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in